Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) EBT Margin (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EBT Margin for 7 consecutive years, with 201.92% as the latest value for Q1 2025.

  • On a quarterly basis, EBT Margin rose 13972.0% to 201.92% in Q1 2025 year-over-year; TTM through Sep 2025 was 717.23%, a 47118.0% decrease, with the full-year FY2024 number at 245.13%, up 2491.0% from a year prior.
  • EBT Margin was 201.92% for Q1 2025 at Whitehawk Therapeutics, up from 252.42% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 675.77% in Q2 2021 to a low of 4563.33% in Q1 2021.
  • A 5-year average of 501.68% and a median of 262.91% in 2022 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 396268bps in 2022; the steepest drop was -120705bps in 2022.
  • Whitehawk Therapeutics' EBT Margin stood at 114.21% in 2021, then tumbled by -133bps to 266.35% in 2022, then grew by 3bps to 257.18% in 2023, then rose by 2bps to 252.42% in 2024, then grew by 20bps to 201.92% in 2025.
  • Per Business Quant, the three most recent readings for WHWK's EBT Margin are 201.92% (Q1 2025), 252.42% (Q4 2024), and 173.95% (Q3 2024).